|
Gene: CCDC124 |
Gene summary for CCDC124 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CCDC124 | Gene ID | 115098 |
Gene name | coiled-coil domain containing 124 | |
Gene Alias | Lso2 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | A0A024R7M8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
115098 | CCDC124 | ATC13 | Human | Thyroid | ATC | 4.49e-37 | 9.88e-01 | 0.34 |
115098 | CCDC124 | ATC1 | Human | Thyroid | ATC | 6.79e-12 | 5.65e-01 | 0.2878 |
115098 | CCDC124 | ATC2 | Human | Thyroid | ATC | 1.14e-20 | 1.81e+00 | 0.34 |
115098 | CCDC124 | ATC3 | Human | Thyroid | ATC | 1.56e-08 | 5.00e-01 | 0.338 |
115098 | CCDC124 | ATC4 | Human | Thyroid | ATC | 2.92e-23 | 6.43e-01 | 0.34 |
115098 | CCDC124 | ATC5 | Human | Thyroid | ATC | 3.25e-39 | 1.06e+00 | 0.34 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC124 | SNV | Missense_Mutation | novel | c.178C>T | p.Arg60Cys | p.R60C | Q96CT7 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
CCDC124 | insertion | Frame_Shift_Ins | novel | c.131_132insGTGGAGATGGGGTTTTGCCGTGTTGGCC | p.His45TrpfsTer32 | p.H45Wfs*32 | Q96CT7 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CCDC124 | SNV | Missense_Mutation | novel | c.431N>T | p.Ala144Val | p.A144V | Q96CT7 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCDC124 | SNV | Missense_Mutation | novel | c.559N>C | p.Glu187Gln | p.E187Q | Q96CT7 | protein_coding | deleterious(0.02) | possibly_damaging(0.848) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
CCDC124 | SNV | Missense_Mutation | novel | c.424N>A | p.Val142Met | p.V142M | Q96CT7 | protein_coding | tolerated(0.17) | possibly_damaging(0.628) | TCGA-AA-3531-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCDC124 | SNV | Missense_Mutation | rs762625853 | c.176N>A | p.Arg59Gln | p.R59Q | Q96CT7 | protein_coding | deleterious(0.01) | benign(0.089) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCDC124 | SNV | Missense_Mutation | rs778475492 | c.124N>A | p.Asp42Asn | p.D42N | Q96CT7 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCDC124 | SNV | Missense_Mutation | c.212N>G | p.Gln71Arg | p.Q71R | Q96CT7 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCDC124 | SNV | Missense_Mutation | rs758756227 | c.127N>A | p.Asp43Asn | p.D43N | Q96CT7 | protein_coding | deleterious(0.03) | probably_damaging(0.955) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCDC124 | SNV | Missense_Mutation | c.337N>A | p.Ala113Thr | p.A113T | Q96CT7 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-F5-6812-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |